1. Home
  2. PASG vs FEMY Comparison

PASG vs FEMY Comparison

Compare PASG & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PASG

Passage Bio Inc.

HOLD

Current Price

$5.20

Market Cap

26.0M

Sector

Health Care

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.43

Market Cap

21.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PASG
FEMY
Founded
2017
2004
Country
United States
United States
Employees
27
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.0M
21.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PASG
FEMY
Price
$5.20
$0.43
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$14.00
$5.50
AVG Volume (30 Days)
64.6K
446.6K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
N/A
$2,293,313.00
Revenue This Year
N/A
$105.16
Revenue Next Year
N/A
$200.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
40.77
52 Week Low
$0.35
$0.31
52 Week High
$20.00
$1.11

Technical Indicators

Market Signals
Indicator
PASG
FEMY
Relative Strength Index (RSI) 42.65 58.01
Support Level $3.94 $0.34
Resistance Level $5.74 $0.46
Average True Range (ATR) 0.38 0.04
MACD 0.18 0.00
Stochastic Oscillator 69.53 72.78

Price Performance

Historical Comparison
PASG
FEMY

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: